# K213071: MOTOTM Partial Knee & MOTO PFJ Systems Extension

- Pathway: 510(k) (Traditional)
- Applicant: Medacta International S.A.
- Decided: Nov 16, 2021 after 54 days
- Product code: HSX (Prosthesis, Knee, Femorotibial, Non-Constrained, Cemented, Metal/Polymer)
- Device class: 2
- Regulation: 21 CFR 888.3520
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 5 generations back to K880155 (1988). 18 ancestors in all.
1 later device descends from it; 1 cites it directly.
0 of 20 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K162084: MOTO Partial Knee System, Medacta International S.A. (2017) Summary page 5.
- K183029: MOTO Partial Knee System, Medacta International S.A. (2019) Summary page 4.
- K200122: MOTO PFJ System, Medacta International S.A. (2020) Summary page 4.

## Most influential descendants
- K251618: MOTO Partial Knee System Extension (2025), 0 descendants of its own

## Indications for use
The MOTO™ Partial Knee System is designed for cemented use in partial knee arthroplasty, if there is evidence of sufficient sound bone to seat and support the components. Partial replacement of the articulating surfaces of the knee is indicated when only one compartment of the joint is affected due to the compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity or revision of previous arthroplasty. The MOTO™ PFJ is designed for cemented use in partial knee arthroplasty, if there is evidence of enough sound bone to seat and support the components. Patellofemoral replacement is indicated in the following cases: * Osteoarthritis, post-traumatic arthritis, polyarthritis, severe chondrocalcinosis of the patellofemoral joint. * Previously failed surgical attempts (i.e. arthroscopy, lateral release, tibial tubercle elevation, cartilage transplantation). * History of patellar dislocation or fracture, resulting in cartilage degeneration of the patellofemoral joint. * Degeneration induced by dysplasia. If the surgeon evaluates an unequivocal indication for replacement of the patellofemoral joint, with or without a patella resurfacing, which outweighs the risks associated with the surgery, PFJ replacement may be considered, particularly for young patients.

Source page: https://510kreport.com/device/K213071
Methodology: https://510kreport.com/methodology